Endometrial cancer treatment and outcomes in Argentina: ECHOS-A real-world study

• Published in: Gynecologic oncology reports 2024-08, Vol.54, p.101457, Article 101457
• Main Authors: Soares, Claudia, Abreu, Gabriela, Queiroz, Juliana, da Silva, Thiago Luiz Nogueira, Menezes, Patrícia, Carrizo, Mariano, Scibona, Paula, Savoy, Nadia Elisabeth, Simonovich, Ventura A., Riggi, María Cecilia, Odetto, Diego, Cravero, Florencia, Jotimliansky, Laura
• Format: Article
• Language: English
• Subjects: Argentina; Endometrial cancer; Latin America; Overall survival; Progression-free survival; Real world; Research Report
• ISSN: 2352-5789; 2352-5789
• DOI: 10.1016/j.gore.2024.101457

[Display omitted] •In the Endometrial Cancer Health Outcomes Study in Argentina (ECHOS-A), approximately one-quarter of patients received no treatment.•Over one-third of patients with advanced endometrial cancer were not treated with systemic therapy.•There was no preferred regimen in the second-line setting.•ECHOS-A highlights the urgent need for improved treatment strategies in endometrial cancer, particularly in the second-line setting. Real-world data for patients with endometrial cancer (EC) are limited, particularly in Latin America. We present treatment pattern findings from ECHOS-A – Endometrial Cancer Health Outcomes Study in Argentina. A retrospective study using clinical data from privately insured patients with EC diagnosed from 2010 to 2019. Index (diagnosis proxy) was first date of an EC-related health term or treatment. Demographics, clinical characteristics, and FIGO staging were described. Disease progression and survival were assessed until study end, loss to follow-up, or death. Of 805 patients with EC, 77.4 % (n = 623/805) received any treatment and 22.6 % (n = 182/805) received none. Among those treated, 31.8 % (n = 198/623) had first-line (1L) systemic therapy, and 45.5 % (n = 90/198) proceeded to second-line (2L) therapy. Mean follow-up was 33.6 (SD 31.8) months. Of those receiving any treatment, 87.3 % (n = 544/623) had FIGO stage data (I, 62.9 %; II, 18.6 %; III, 13.6 %; IV, 5.0 %). Treatment by class in 1L and 2L, respectively, were platinum chemotherapy, 73.7 %, 36.7 %; non-platinum chemotherapy, 73.7 %, 62.2 %; immunotherapy, 1.0 %, 11.1 %; hormone therapy, 17.7 %, 26.7 %. Carboplatin/paclitaxel was the most frequent 1L (52.5 %) and 2L (14.4 %) regimen. Mean time to progression was 14.1 (SD 16.3) and 8.8 (SD 8.3) months in 1L and 2L, respectively. Adjusted 1- to 5-year risk of progression/death was 46.5–77.5 % and 65.0–86.2 % in 1L and 2L, respectively. Approximately one-quarter of patients with EC received no treatment, and approximately two-thirds were not treated with 1L systemic therapy. Efforts to better understand the reasons for these treatment patterns are crucial for improving patient outcomes.